Using Elecsys® anti-SARS-CoV-2 test, we assessed 42 people vaccinated with Abdala candidate and 15 days after immunization their sera showed high antibody titers, the Cuban scientists stated.

There was a high correlation between the Cuban UMELISA SARS-CoV-2 antiRBD test used during clinical trials and the conclusions of Roche’s Elecsys®.

Those who received Abdala vaccine candidate achieved antibody titers through Elecsys® anti-SARS-CoV-2 comparable to those of Pfizer / BionTech vaccines when using the same test.

Abdala candidate, authorized by national regulatory authorities for emergency use, proved high effectiveness (92.28%) in phase III of clinical trials to reduce transmission, and over 90% to cut down severity and mortality rates.

Soberana 02 and Soberana Plus vaccine candidates, both developed by the Finlay Vaccine Institute (FVI), showed 91.2% effectiveness during their clinical trials.

pgh/pll / mgt / znc